Loading...
Market
What will be the regulatory response to the norovirus vaccine trial results by December 31, 2025?
2
Resolution / Starting Odds
Fast-tracked approval • 25%
Standard approval process • 25%
Request for more data • 25%
Rejection • 25%
Announcements from health regulatory bodies such as the MHRA or EMA
Story
British Volunteers to Trial World's First Norovirus Vaccine Against Winter Vomiting Bug
Oct 22, 2024, 11:14 PM
British researchers are set to trial the world's first vaccine against the vomiting bug norovirus. The vaccine, which will be tested on thousands of British volunteers, aims to combat the winter vomiting bug. The trial seeks to provide a preventive measure against norovirus, a common and highly contagious virus that causes gastroenteritis, according to BBCDorset.
View original story
Similar markets
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Successful efficacy • 25%
Partial efficacy • 25%
No efficacy • 25%
Trial discontinued • 25%
Full approval • 25%
Emergency use authorization • 25%
Conditional approval • 25%
No approval • 25%
Successful with strong immune response • 25%
Moderate success • 25%
No significant effect • 25%
Trial halted • 25%
Clinical hold lifted with no changes • 25%
Clinical hold lifted with additional requirements • 25%
Clinical hold maintained • 25%
Clinical hold converted to full stop • 25%
Partnership with another company • 25%
Focus on different vaccine candidates • 25%
Continue with current strategy • 25%
Other strategic response • 25%
Mostly positive • 25%
Mostly negative • 25%
Mixed • 25%
Indifferent • 25%
Hold lifted with no conditions • 25%
Hold lifted with conditions • 25%
Hold extended • 25%
Hold converted to permanent suspension • 25%
Approval revoked • 25%
Approval maintained • 25%
Approval revised • 25%
No decision • 25%